Azenta and Form Bio Partner to Enhance AAV Gene Therapy

Azenta Life Sciences and Form Bio have announced a strategic partnership to enhance adeno-associated virus (AAV) gene therapy development. Announced in a press release, the collaboration aims to integrate GENEWIZ's next-generation sequencing services with Form Bio's AI-powered analysis pipelines.

The partnership focuses on providing gene therapy developers with data-driven insights into AAV capsid contents, improving safety, efficacy, and manufacturability. GENEWIZ will offer synthesis and packaging of transgene expression cassettes, along with high-quality, long-read sequencing services. Form Bio will utilize its Long-read AAV Analysis (LAAVA) software for comprehensive AAV Genome Integrity Characterization, offering actionable insights through detailed reporting.

This collaboration is set to officially launch at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in May 2025, where both companies will present their work on integrating sequencing and analysis workflows to accelerate the development of innovative therapies.